Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.
Brand Name : Norliqva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 14, 2021
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Amlodipine Besylate,Celecoxib
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Coeptis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Burke Therapeutics, LLC Signs Exclusive US Marketing and Supply Agreement
Details : Burke will market the fixed-dose combination drug, Consensi to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 11, 2020
Lead Product(s) : Amlodipine Besylate,Celecoxib
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Coeptis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?